Volume 2.15 | Apr 25

Dermal Cell News 2.15 April 25, 2016
Dermal Cell News
     In this issue: Publications | Reviews | Science News | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  DCN on Twitter
Researchers One Step Closer to Understanding Regeneration in Mammals
Researchers showed that a species of spiny mouse, Acomys cahirinus, could completely close four millimeter ear holes and regenerate the missing tissue. They examined repair of ear holes across a number of different mammals and revealed that regeneration appears to be a unique trait. [Press release from University of Kentucky discussing online publication in Nature Communications] Press Release | Full Article
Watch Video MesenTrek Rise of Enriched Mouse MSC Cultures
PUBLICATIONS (Ranked by impact factor of the journal)

Epidermal Notch1 Recruits RORγ+ Group 3 Innate Lymphoid Cells to Orchestrate Normal Skin Repair
The authors showed that Notch1 works as a damage response signal. Epidermal Notch induced recruitment of immune cell subsets including RORγ+ ILC3s into wounded dermis; RORγ+ ILC3s were potent sources of IL17F in wounds and control immunological and epidermal cell responses. [Nat Commun] Full Article

Knockdown of LncRNA-ATB Suppresses Autocrine Secretion of TGF-β2 by Targeting ZNF217 via miR-200c in Keloid Fibroblasts
Researchers investigated the role of long non-coding RNA (lncRNA)-activated by transforming growth factor-β (TGF-β) (lncRNA-ATB) in the autocrine secretion of TGF-β in keloid fibroblasts and explored the underlying molecular mechanism. [Sci Rep] Full Article

Skin Barrier Defects Caused by Keratinocyte-Specific Deletion of ADAM17 or EGFR Are Based on Highly Similar Proteome and Degradome Alterations
Scientists aimed for the first proteomic/degradomic approach to characterize the disruption of the ADAM17–epidermal growth factor receptor (EGFR) signaling axis and its consequences for epidermal barrier formation. [J Proteome Res] Abstract | Graphical Abstract

ILK–PI3K/AKT Pathway Participates in Cutaneous Wound Contraction by Regulating Fibroblast Migration and Differentiation to Myofibroblast
Using in vitro studies, researchers demonstrated that integrin-linked kinase (ILK) and PI3K/AKT inhibitors suppressed the contraction of fibroblast-populated collagen lattices, inhibited fibroblast migration, and interrupted the effect of TGF-β1 on promoting alpha smooth muscle actin expression in fibroblasts. [Lab Invest] Abstract

Modeling Fibrosis Using Fibroblasts Isolated from Scarred Rat Vocal Folds
Given the importance of scar vocal fold fibroblasts (VFFs) to phenotypically appropriate in vitro modeling of VF fibrosis, investigators pursued detailed characterization of scar VFFs obtained from surgically injured rat VF mucosae, compared with those obtained from experimentally naïve, age-matched tissue. [Lab Invest] Abstract


The Transcription Factor RUNX2 Regulates Receptor Tyrosine Kinase Expression in Melanoma
Scientists demonstrated that RUNX2-deficient melanoma cells display a significant decrease in three receptor tyrosine kinases, EGFR, IGF-1R and PDGFRβ. [Oncotarget] Full Article

Use of a MCL-1 Inhibitor Alone to De-Bulk Melanoma and in Combination to Kill Melanoma Initiating Cells
Researchers examined the effects of the MCL-1 inhibitor SC-2001 in killing non melanoma-initiating-cells (bulk of melanoma), and melanoma-initiating-cells. [Oncotarget] Full Article

TET2 Negatively Regulates Nestin Expression in Human Melanoma
Investigators provide evidence suggesting that nestin regulation is negatively controlled epigenetically by translocation methylcytosine dioxygenase 2 (TET) 2 via 5-hydroxymethylcytosine binding at the 3′ untranslated region of the nestin gene, providing one potential pathway for understanding melanoma growth characteristics. [Am J Pathol] Abstract

Transcription Factor 7-Like 1 Dysregulates Keratinocyte Differentiation through Upregulating Lipocalin 2
To reveal the potential role of transcription factor 7-like 1 (Tcf7l1) in the dysregulation of keratinocyte differentiation, both Tcf7l1 and lipocalin 2 (LCN2) were determined in a variety of skin disorders. Scientists found that both Tcf7l1 and LCN2 were highly expressed in diseases characterized by defective keratinocyte differentiation (especially psoriasis vulgaris, condyloma acuminatum, squamous cell carcinoma, etc.). [Cell Death Disc] Full Article

Weekend-Free Culture hPSCs with mTeSR™1 or TeSR™-E8™
Managing Leptomeningeal Melanoma Metastases in the Era of Immune and Targeted Therapy
The authors outline the clinical course of leptomeningeal melanoma metastases development and describe how the intracranial immune and cellular microenvironments offer both opportunities and challenges for the successful management of this disease. [Int J Cancer] Abstract

Visit our reviews page to see a complete list of reviews in the dermal cell research field.
Immunotherapy Drug Shrinks Tumors in Half of Patients with Rare, Virus-Linked Skin Cancer
In a clinical trial of the immunotherapy drug pembrolizumab, half of 25 patients with a rare type of virus-linked skin cancer called Merkel cell carcinoma experienced substantial tumor shrinkage lasting nearly three times as long, on average, than with conventional chemotherapy. [Press release from The Johns Hopkins University discussing research presented at the 2016 American Association for Cancer Research (AACR) Annual Meeting, New Orleans] Press Release

From our sponsor: Studying ESCs or iPSCs? Request your free copy of the small molecules wallchart.
Bristol-Myers Squibb’s Opdivo® (Nivolumab) Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Previously Treated Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Bristol-Myers Squibb Company announced that the U.S. Food and Drug Administration has granted breakthrough therapy designation to Opdivo for the potential indication of recurrent or metastatic squamous cell carcinoma of the head and neck after platinum based therapy. [Bristol-Myers Squibb Company] Press Release

SpinalCyte, LLC Announces Final Results from Phase II Animal Trials Using Human Dermal Fibroblast Transplantation for Intervertebral Disc Degeneration
SpinalCyte, LLC announced the final results of Phase II Animal Studies for Transplantation of human dermal fibroblasts for Intervertebral Disc Degeneration. [SpinalCyte, LLC] Press Release

AbbVie, University of Chicago Collaborate to Advance Cancer Research
The University of Chicago and AbbVie have entered into a five-year collaboration agreement designed to improve the pace of discovery and advance medical research in oncology at both organizations. [The University of Chicago] Press Release
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW Summit for Cancer Immunotherapy
June 26-29, 2016
Halifax, Canada

Visit our events page to see a complete list of events in the dermal cell community.
NEW Postdoctoral Position – Cancer Biology/Immunology (The University of Texas MD Anderson Cancer Center)

Postdoctoral Scientist – Molecular Oncology Group (Cancer Research UK Manchester Institute)

Faculty Position – Tumor Immunology (John Wayne Cancer Institute at Providence Saint John’s Health Center)

Postdoctoral Position – Stem Cell Biology and Tissue Engineering (Northeastern University)

Skincare Applied Research Manager (L’Oreal)

Senior Bioinformatician – Cutaneous Medicine (Guy’s & St. Thomas’ NHS Foundation Trust)

Postdoctoral Research Fellow – Cancer and Inflammatory Diseases of the Skin (Weill Cornell Medical College)

Postdoctoral Positions – Tissue Repair/Inflammation (Institut Pasteur)

Faculty Position – Radiation Biology (Yale University)

Research Technician – Tumor Initiation and Metastasis (Fred Hutchinson Cancer Research Center)

PhD Position – Stem Cells and Developmental Biology (Vienna Biocenter)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Dermal Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Dermal Cell News: Archives | Events | Contact Us